Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CVAX-01
- Development stage
- Unknown
- Lead developer
- CastleVax
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
CVAX-01 is an intranasal COVID-19 vaccine candidate developed by CastleVax, a clinical-stage spin-off from the Icahn School of Medicine at Mount Sinai. The vaccine utilizes a live-attenuated Newcastle Disease Virus (NDV) vector platform to express a stabilized version of the SARS-CoV-2 spike protein. Unlike traditional intramuscular vaccines, CVAX-01 is administered via a nasal spray to induce mucosal immunity (secretory IgA) in the upper respiratory tract, aiming to block viral entry and reduce transmission in addition to preventing severe disease. In 2024, the program received significant backing, including a $34 million grant from BARDA to fund a 10,000-participant Phase 2b trial, and support from the New York State Biodefense Commercialization Fund. The vaccine is delivered using AptarGroup's specialized intranasal delivery devices.
- Other names
- CastleVax COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on CVAX-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVAX-01.